ENT（耳鼻咽喉科）疾患治療の世界市場...市場調査レポートについてご紹介

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: Disease overview

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by disease
• Global rhinitis treatment market
• Global sinusitis treatment market
• Global otitis media treatment market
• Global tonsillitis treatment market

PART 09: Geographical segmentation
• ENT disorder treatment market in Americas
• ENT disorder treatment market in EMEA
• ENT disorder treatment market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments

PART 12: Market trends
• Growing consolidation in industry particularly for rhinitis
• Increase in research on allergic disorders
• Awareness about controlled usage of antibiotics

PART 13: Vendor landscape
• Competitive landscape

PART 14: Key vendor analysis
• ALK
• GSK
• Novartis
• Sanofi
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits] 
Exhibit 01: Some major treatments associated with sinusitis
Exhibit 02: Snapshot: Global ENT disorder treatment market
Exhibit 03: Global ENT disorder treatment market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis: Global ENT disorder treatment market
Exhibit 05: Five forces analysis
Exhibit 06: Key pipeline by vendors
Exhibit 07: Pipeline landscape
Exhibit 08: Global ENT disorder treatment market segmentation by disease type
Exhibit 09: Market snapshot: Global ENT disorder market by disease type 2016-2021
Exhibit 10: Types of rhinitis
Exhibit 11: Major types of allergic rhinitis
Exhibit 12: Global rhinitis treatment market 2016-2021 ($ millions)
Exhibit 13: Types of sinusitis
Exhibit 14: Some drugs approved for sinusitis
Exhibit 15: Global sinusitis treatment market 2016-2021 ($ millions)
Exhibit 16: Otitis media therapy in pipeline
Exhibit 17: Global otitis media treatment market 2016-2021 ($ millions)
Exhibit 18: Global tonsillitis treatment market 2016-2021 ($ millions)
Exhibit 19: ENT disorder treatment market by geography 2016 and 2021
Exhibit 20: ENT disorder treatment market by geography 2016-2021 ($ millions)
Exhibit 21: Market scenario in Americas
Exhibit 22: ENT disorder treatment market in Americas 2016-2021 ($ millions)
Exhibit 23: Market scenario in EMEA
Exhibit 24: ENT disorder treatment market in EMEA 2016-2021 ($ millions)
Exhibit 25: Market scenario in APAC
Exhibit 26: ENT disorder treatment market in APAC 2016-2021 ($ millions)
Exhibit 27: ENT disorders triggered by various pollutants
Exhibit 28: Adult population with sinusitis and chronic rhinitis in US 2014 (million)
Exhibit 29: Impact of drivers
Exhibit 30: Antibiotic resistance development steps
Exhibit 31: Few landmark generic version of branded drugs
Exhibit 32: Impact of challenges
Exhibit 33: Major causes of antibiotic resistance
Exhibit 34: Competitive structure analysis of global ENT disorder treatment market 2016
Exhibit 35: Competitive analysis of global ENT disorder treatment market
Exhibit 36: ALK: Key highlights
Exhibit 37: ALK: Strength assessment
Exhibit 38: ALK: Strategy assessment
Exhibit 39: ALK: Opportunity assessment
Exhibit 40: GSK: Key highlights
Exhibit 41: GSK: Strength assessment
Exhibit 42: GSK: Strategy assessment
Exhibit 43: GSK: Opportunity assessment
Exhibit 44: GSK: YoY growth rate of Avamys/Veramyst 2014 and 2015 ($ millions)
Exhibit 45: Novartis: Key highlights
Exhibit 46: Novartis: Strength assessment
Exhibit 47: Novartis: Strategy assessment
Exhibit 48: Novartis: Opportunity assessment
Exhibit 49: Sanofi: Key highlights
Exhibit 50: Sanofi: Strength assessment
Exhibit 51: Sanofi: Strategy assessment
Exhibit 52: Sanofi: Opportunity assessment
Exhibit 53: Sanofi: YoY growth rate of Allegra 2014 and 2015 ($ millions)